Yiqi Xia , Wenhui Zhu , Zhenyu Shi , Yang Shen , Chengsen Cui , Jinxu Ai , Yemin Yuan , Xin Ye , Dawei Zhu , Ping He
{"title":"中国40岁及以上成年人带状疱疹疫苗接种覆盖率及其相关因素:一项基于人群的调查","authors":"Yiqi Xia , Wenhui Zhu , Zhenyu Shi , Yang Shen , Chengsen Cui , Jinxu Ai , Yemin Yuan , Xin Ye , Dawei Zhu , Ping He","doi":"10.1016/j.vaccine.2025.127122","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Herpes zoster (HZ) is a significant public health issue in China, especially with an aging population and rising incidence. While vaccination effectively prevents HZ and its complications, national data on HZ vaccine (HZV) coverage and associated factors in China are limited.</div></div><div><h3>Methods</h3><div>We conducted a nationwide survey across 25 provinces in mainland China, including 14,315 participants aged over 40 years, to estimate HZV uptake and associated factors among adults aged 40 years and older. Multivariate logistic regression was used to assess characteristics linked to vaccination, and we analysed vaccine types and dose completion rates.</div></div><div><h3>Results</h3><div>The HZV uptake rate was 0.79 %. Vaccination was more likely among individuals with middle school education and higher household income. Most vaccinated individuals received the zoster vaccine live (ZVL) rather than the recombinant zoster vaccine (RZV), and nearly half completed two doses.</div></div><div><h3>Conclusions</h3><div>HZV coverage in China is low, underscoring the need for targeted public health strategies to improve vaccine accessibility and awareness, particularly among at-risk groups, to reduce HZ-related burdens.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"56 ","pages":"Article 127122"},"PeriodicalIF":4.5000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Herpes zoster vaccination coverage and factors associated among adults aged 40 and older in China: A population-based survey\",\"authors\":\"Yiqi Xia , Wenhui Zhu , Zhenyu Shi , Yang Shen , Chengsen Cui , Jinxu Ai , Yemin Yuan , Xin Ye , Dawei Zhu , Ping He\",\"doi\":\"10.1016/j.vaccine.2025.127122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>Herpes zoster (HZ) is a significant public health issue in China, especially with an aging population and rising incidence. While vaccination effectively prevents HZ and its complications, national data on HZ vaccine (HZV) coverage and associated factors in China are limited.</div></div><div><h3>Methods</h3><div>We conducted a nationwide survey across 25 provinces in mainland China, including 14,315 participants aged over 40 years, to estimate HZV uptake and associated factors among adults aged 40 years and older. Multivariate logistic regression was used to assess characteristics linked to vaccination, and we analysed vaccine types and dose completion rates.</div></div><div><h3>Results</h3><div>The HZV uptake rate was 0.79 %. Vaccination was more likely among individuals with middle school education and higher household income. Most vaccinated individuals received the zoster vaccine live (ZVL) rather than the recombinant zoster vaccine (RZV), and nearly half completed two doses.</div></div><div><h3>Conclusions</h3><div>HZV coverage in China is low, underscoring the need for targeted public health strategies to improve vaccine accessibility and awareness, particularly among at-risk groups, to reduce HZ-related burdens.</div></div>\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"56 \",\"pages\":\"Article 127122\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X25004190\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25004190","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Herpes zoster vaccination coverage and factors associated among adults aged 40 and older in China: A population-based survey
Objectives
Herpes zoster (HZ) is a significant public health issue in China, especially with an aging population and rising incidence. While vaccination effectively prevents HZ and its complications, national data on HZ vaccine (HZV) coverage and associated factors in China are limited.
Methods
We conducted a nationwide survey across 25 provinces in mainland China, including 14,315 participants aged over 40 years, to estimate HZV uptake and associated factors among adults aged 40 years and older. Multivariate logistic regression was used to assess characteristics linked to vaccination, and we analysed vaccine types and dose completion rates.
Results
The HZV uptake rate was 0.79 %. Vaccination was more likely among individuals with middle school education and higher household income. Most vaccinated individuals received the zoster vaccine live (ZVL) rather than the recombinant zoster vaccine (RZV), and nearly half completed two doses.
Conclusions
HZV coverage in China is low, underscoring the need for targeted public health strategies to improve vaccine accessibility and awareness, particularly among at-risk groups, to reduce HZ-related burdens.
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.